Thomas Herzog

Thomas J. Herzog

Clinical Director University of Cincinnati Cancer Institute and Professor, Obstetrics and Gynecology, UC College of Medicine

Medical Sciences Building


COM Ob/Gyn Gynecologic Oncology - 0526

University of Cincinnati Cancer Institute
3255 Eden Avenue, Suite 250B
Cincinnati, Ohio 45019


Bachelors Degree, Miami University Cincinnati, OH, 1982 (Zoology)

Medical Degree, University of Cincinnati Cincinnati, OH, 1986 (Obstetrics and Gynecology Gynecologic Oncology)

Residency, Good Samaritan Hospital Cincinnati, OH, 1990 (Obstetrics and Gynecology)

Fellowship, Washington University School of Medicine St. Louis, MO, 1993 (Gynecologic Oncology)

Clinical Focus

Gynecologic Oncology

Obstetrics and Gynecology



Gynecologic Oncology

Obstetrics and Gynecology


American Board of Obstetrics and Gynecology (Gynecologic Oncology)


American Board of Obstetrics and Gynecology



Peer Reviewed Publications

Herzog T.J.;Monk B.J.;Rose P.G.;Braly P.;Hines J.F.;Bell M.C.;Wenham R.M.;Secord A.A.;Roman L.D.;Einstein M.H.;Drake R.D.;Childs B.H. (01-01-2014. ) A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer.Gynecologic Oncology, , 132 (3 ) ,517-525

Wright J.;Ananth C.;Tsui J.;Glied S.;Burke W.;Lu Y.;Neugut A.;Herzog T.;Hershman D. (01-01-2014. ) Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.Cancer, , 120 (8 ) ,1246-1254

Du Bois A.;Floquet A.;Kim J.W.;Rau J.;Del Campo J.M.;Friedlander M.;Pignata S.;Fujiwara K.;Vergote I.;Colombo N.;Mirza M.R.;Monk B.J.;Kimmig R.;Ray-Coquard I.;Zang R.;Diaz-Padilla I.;Baumann K.H.;Mouret-Reynier M.A.;Kim J.H.;Kurzeder C.;Lesoin A.;Vasey P.;Marth C.;Canzler U.;Scambia G.;Shimada M.;Calvert P.;Pujade-Lauraine E.;Kim B.G.;Herzog T.J.;Mitrica I.;Schade-Brittinger C.;Wang Q.;Crescenzo R.;Harter P. (10-20-2014. ) Incorporation of pazopanib in maintenance therapy of ovarian cancer.Journal of Clinical Oncology, , 32 (30 ) ,3374-3381

Burke W.M.;Orr J.;Leitao M.;Salom E.;Gehrig P.;Olawaiye A.B.;Brewer M.;Boruta D.;Villella J.;Herzog T.;Shahin F.A. (01-01-2014. ) Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc.Gynecologic Oncology, , 135 (3 ) ,625

Floquet A.;Vergote I.;Colombo N.;Fiane B.;Monk B.J.;Reinthaller A.;Calvert P.;Herzog T.J.;Meier W.;Kim J.W.;Campo J.M.D.;Friedlander M.;Pisano C.;Isonishin S.;Crescenzo R.J.;Barrett C.;Wang K.;Mitrica I.;Bois A.D. (01-01-2015. ) Progression-free survival by local investigator versus independent central review: Comparative analy.Gynecologic Oncology, , 136 (1 ) ,37-42

Berek J.S.;Edwards R.P.;Parker L.P.;Demars L.R.;Herzog T.J.;Lentz S.S.;Morris R.T.;Akerley W.L.;Holloway R.W.;Method M.W.;Plaxe S.C.;Walker J.L.;Friccius-Quecke H.;Krasner C.N. (01-01-2014. ) Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian .International Journal of Gynecological Cancer, , 24 (9 ) ,1583-1589

Herzog T.;Coleman R.;Monk B.;Armstrong D.;Alvarez R. (05-01-2015. ) In assessing surrogate clinical trial end points: Drug safety is a requisite.Journal of Clinical Oncology, , 33 (13 ) ,1511-1512

Jackson A.;Eisenhauer E.;Herzog T. (01-01-2015. ) Emerging therapies: Angiogenesis inhibitors for ovarian cancer.Expert Opinion on Emerging Drugs, , 20 (2 ) ,331-346

Previs R.;Leath C.;Coleman R.;Herzog T.;Krivak T.;Brower S.;Tian C.;Secord A. (01-01-2015. ) Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca.Gynecologic Oncology, , 138 (2 ) ,267-271

Post Graduate Training and Education

1986-1990 Residency in Obstetrics and Gynecology , Good Samaritan Hospital , , Cincinnati, Ohio

1990-1993 Fellow In Gynecologic Oncology, Washington University School of Medicine, , St. Louis, MO

Contact Information

Academic - University of Cincinnati Cancer Institute
3255 Eden Avenue, Suite 250B
CincinnatiĀ  Ohio, 45019
Phone: 513-558-2177
Fax: 513-558-2666